As shown in (Figure 4A, Table 4), plasma COMP levels were significantly lower in MFS patients than in age- and sex-matched controls (MFS: 136.40 ± 37.61 vs control: 346.30 ± 76.14; P = 0.021), suggesting a dramatic reduction in COMP levels during the pathogenic progression of MFS. The gene discussed is COMP; the disease is Marfan syndrome.